A Phase 2/3 multicenter study of Osivelotor has been approved to proceed by India’s Central Drugs Standard Control Organisation (CDSCO). Aimed at treating Sickle Cell Disease, the drug (GBT021601) has shown promising results in both safety and efficiency.
Consisting of three distinct phases, the trial highlights the potential benefits offered by Osivelotor as a treatment option for those with sickle cell disease:
I. Evaluating optimal dosages for adult participants.
II. Comparing drug efficiency results against placebo for adults and pediatric patients over 48 weeks.
III. Analyzing pediatric patients’ body reactions to Osivelotor treatments.
OxyDial team is thrilled with the continued efforts by pharma leaders to improve quality of life for those with blood disorders, and are eager to see further traction and promising results as these trials proceed.
Read more about the trial: https://lnkd.in/enshBrsu
See the CDSCO approval news: https://lnkd.in/etQcZTr6